[Periocular basal cell carcinoma treatment tendencies].
E
E
García Martín
F J
FJ
Fernández Tirado
D000622:Aminolevulinic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D000634:Aminoquinolines / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002280:Basal Cell Carcinoma / Q000188:drug therapy* / Q000453:epidemiology / Q000601:surgery; D003230:Conjunctival Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000601:surgery; D005142:Eyelid Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000601:surgery; D006801:Humans; D000077271:Imiquimod; D007155:Immunologic Factors / Q000627:therapeutic use*; D015580:Mohs Surgery; D009381:Neoplasms, Radiation-Induced / Q000188:drug therapy / Q000453:epidemiology / Q000601:surgery; D017060:Patient Satisfaction; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D013472:Sunlight / Q000009:adverse effects
D000634:Aminoquinolines; D000970:Antineoplastic Agents; D007155:Immunologic Factors; D017319:Photosensitizing Agents; C475457:methyl 5-aminolevulinate; D000622:Aminolevulinic Acid; D000077271:Imiquimod